Anaplastic Thyroid Carcinoma and Targeted Therapies: A Survey

www.surveyx.cn

Abstract

Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer subtype with poor prognosis, often associated with BRAFV600E mutations. This survey paper explores the current landscape of targeted therapies, focusing on kinase inhibitors like Dabrafenib and Trametinib, which target the MAPK/ERK pathway, and immune checkpoint blockade (ICB) using agents such as pembrolizumab. Despite the efficacy of these therapies, challenges remain due to resistance mechanisms and adverse effects. The combination of BRAF inhibitors with ICB shows promise, leveraging synergistic effects to enhance antitumor responses. The development of next-generation inhibitors, such as PLX8394, aims to overcome resistance by selectively targeting mutant BRAF without activating the MAPK pathway. The integration of predictive models and personalized medicine approaches is crucial for optimizing treatment strategies. Ongoing research into tumor-immune interactions and the refinement of combination therapies hold potential for improving patient outcomes in ATC. This paper underscores the importance of continued innovation and strategic therapy integration to address the complexities of ATC treatment.

1 Introduction



Figure 1: chapter structure

1.1 Overview of Anaplastic Thyroid Carcinoma

Anaplastic thyroid carcinoma (ATC) is a rare yet highly aggressive subtype of thyroid cancer, characterized by rapid progression and poor prognosis, which poses significant treatment challenges. Although ATC accounts for a small fraction of thyroid cancer cases, it is responsible for a disproportionate number of related mortalities due to its inherent resistance to conventional therapies. The disease is characterized by rapid tumor growth and a high degree of treatment resistance, contributing to elevated morbidity and mortality rates. The frequent BRAFV600E mutations found in ATC are associated with aggressive tumor behavior and adverse outcomes [1]. The molecular landscape of ATC involves critical signaling pathways, including MAPK and PI3K, which play essential roles in thyroid tumorigenesis and represent potential targets for innovative therapeutic strategies. Addressing the complexities of ATC requires a multidisciplinary approach that integrates advanced diagnostic and therapeutic methodologies to improve patient outcomes [2].

1.2 Significance of Targeted Therapies

Targeted therapies have significantly transformed the treatment landscape for anaplastic thyroid carcinoma (ATC), particularly where conventional approaches have often been inadequate [3]. Kinase inhibitors, which target the molecular aberrations driving tumor progression in ATC, are central to this paradigm shift [4]. Notably, BRAF inhibitors such as Dabrafenib have shown considerable efficacy in managing BRAF-mutated thyroid cancers, providing a viable therapeutic option for this aggressive cancer type [5].

However, the emergence of resistance mechanisms to BRAF and MEK inhibitors presents a significant challenge, underscoring the need for ongoing research and innovation in this field [3]. Additionally, the cardiotoxic effects associated with MEK inhibitors like Trametinib necessitate careful management of adverse events to maintain patient compliance and enhance quality of life [4].

Targeted therapies align with the broader movement towards personalized medicine, aiming to tailor treatments to the unique genetic and molecular profiles of individual tumors, thereby improving therapeutic efficacy and optimizing patient outcomes [3]. Despite the high costs and lengthy timelines involved in drug development, the strategic optimization of kinase-targeted therapies remains crucial, as their potential to significantly enhance the treatment approach for ATC highlights the importance of continued exploration and refinement in this area [4].

1.3 Role of Immune Checkpoint Blockade

Immune checkpoint blockade (ICB) represents a significant advancement in cancer immunotherapy, offering promising therapeutic potential for anaplastic thyroid carcinoma (ATC). Immune checkpoints like CTLA-4 and PD-1 are vital regulators of immune responses, maintaining self-tolerance and modulating the duration and amplitude of immune reactions [6]. However, ATC tumors can exploit these pathways to evade immune detection, facilitating tumor survival and progression [7].

The expression of PD-L1 in ATC tumors indicates the potential for immune checkpoint inhibitors (ICIs) such as pembrolizumab to enhance antitumor immunity by blocking these inhibitory pathways [8]. ICB therapy has shown the ability to elicit robust antitumor responses by reinvigorating T cells and restoring their capacity to target cancer cells [9]. The interplay between BRAF inhibitors and immune modulation further highlights the relevance of ICB in ATC, as BRAF inhibitors can affect immune responses and chemokine secretion, potentially enhancing the effectiveness of checkpoint blockade strategies [10].

Despite these advancements, the application of ICIs in ATC faces challenges, including intrinsic and acquired resistance mechanisms that necessitate a deeper understanding of tumor-immune interactions and strategies to overcome these barriers [11]. Additionally, the endocrine toxicities linked to ICIs, such as hypothyroidism and thyroiditis, require careful management to mitigate adverse effects and improve patient outcomes [12].

Integrating ICB into the therapeutic arsenal for ATC signifies a substantial leap in harnessing the immune system to combat this aggressive cancer. Ongoing research into the complex interactions between tumors and the immune system, along with advancements in refining ICB therapies, holds promise for revealing innovative treatment strategies for ATC. These efforts aim to enhance

immunotherapy efficacy, address tumor heterogeneity challenges, and ultimately improve patient outcomes, including prognosis and survival rates [13, 6].

1.4 Structure of the Survey

This survey is structured to provide a comprehensive exploration of anaplastic thyroid carcinoma (ATC) and the current landscape of targeted therapies. The paper begins with an **Introduction** that discusses the aggressive nature of ATC and the significance of targeted therapies, including BRAF inhibitors and immune checkpoint blockade, in its treatment. The **Background** section delves into the incidence, prognosis, and treatment challenges associated with ATC, focusing on the molecular pathways involved, such as the MAPK/ERK pathway and BRAF mutations.

The subsequent section, **Targeted Therapies for Anaplastic Thyroid Carcinoma**, examines the development and clinical application of targeted therapies, particularly BRAF inhibitors. This is further detailed in the section on **BRAF Inhibitors: Dabrafenib and Trametinib**, which provides an overview of their mechanisms, clinical trials, efficacy, and safety profiles. The paper then explores the **Immune Checkpoint Blockade in Anaplastic Thyroid Carcinoma**, highlighting the mechanisms and therapeutic potential of immune checkpoint inhibitors, along with the associated immune-related adverse events.

The penultimate section, **Combination Therapies and Future Directions**, discusses the potential of combining BRAF inhibitors with immune checkpoint inhibitors and investigates innovative approaches in targeted therapy development. The survey concludes by summarizing the key points discussed and emphasizing the importance of targeted therapies and the potential for combination therapies to improve patient outcomes.The following sections are organized as shown in Figure 1.

2 Background

2.1 Incidence and Prognosis of Anaplastic Thyroid Carcinoma

Anaplastic thyroid carcinoma (ATC), though rare, is a highly lethal thyroid cancer subtype, responsible for a significant portion of thyroid cancer-related deaths [8]. The incidence of ATC has declined despite an overall increase in thyroid cancer cases, driven by the papillary subtype [14]. Survival rates for ATC have shown minimal improvement over the years, indicating persistent management challenges [15]. A study in the Netherlands over three decades highlights these challenges, emphasizing the need for advancements in treatment strategies [15]. Furthermore, geographical differences in epidemiological data add complexity to understanding ATC trends globally [14]. The genetic landscape of ATC frequently includes BRAF mutations, which have spurred the development of targeted therapies focused on the BRAF pathway [16]. Despite these efforts, the prognosis remains poor, underscoring the necessity for novel therapeutic approaches to improve survival and quality of life [17].

2.2 Challenges in Treatment of Anaplastic Thyroid Carcinoma

ATC treatment is fraught with challenges due to its aggressive nature and resistance to conventional therapies. Resistance to BRAF inhibitors is a significant hurdle, often resulting in rapid disease progression [5]. These inhibitors can inadvertently activate the MAPK pathway, promoting RAS-driven tumor growth and diminishing therapeutic effectiveness [18]. The genetic heterogeneity of ATC, including BRAFV600E mutations, complicates treatment by contributing to resistance mechanisms [19]. Resistance to receptor tyrosine kinase inhibitors (RTKIs) further limits long-term management efficacy [20]. Additionally, traditional methods inadequately capture the dynamics of cell migration and proliferation, leading to oversimplified interpretations that hinder effective treatment strategy development [21]. The desmoplastic stroma of ATC's tumor microenvironment also contributes to resistance against standard therapies, with interactions between cancer cells and the immune system, such as the restoration of myeloid-derived suppressor cells (MDSCs) in BRAFi-resistant tumors, complicating outcomes [22]. Furthermore, challenges in detecting gene fusions due to diagnostic limitations hinder personalized therapy approaches [23]. These multifaceted challenges highlight the urgent need for innovative strategies, including personalized therapeutic approaches leveraging molecular profiling and targeted drug delivery, as well as integrating artificial intelligence in diagnostics to enhance risk assessment and outcomes [24, 11, 25, 26].

2.3 Molecular Pathways in Anaplastic Thyroid Carcinoma

The molecular pathways in ATC are characterized by a complex interplay of genetic alterations and signaling networks contributing to its aggressive phenotype and therapeutic resistance. Dysregulation of the MAPK/ERK pathway, primarily due to BRAF mutations like BRAFV600E, is central to ATC pathogenesis, leading to the constitutive activation of this cascade and promoting unchecked cellular proliferation and survival [27]. The structural similarity of ATP binding sites across the kinome complicates the development of selective kinase inhibitors [20]. Besides BRAF mutations, ATC's genetic landscape includes secondary mutations and alternative splicing events that contribute to resistance mechanisms, necessitating comprehensive genomic profiling for effective therapeutic strategy tailoring [23]. The interaction between these molecular alterations and the tumor microenvironment, including immune cell infiltration and chemokine production influenced by BRAF mutations, underscores ATC's molecular complexity [28]. Recent research categorizes protein kinase inhibitors based on their specific targets and clinical applications in disrupting oncogenic pathways [20]. For instance, Trametinib, a MEK inhibitor, uniquely targets the KSR-MEK interface, offering a distinct mechanism compared to other MEK inhibitors [29]. However, drug resistance emergence limits these inhibitors' success, emphasizing the need for innovative therapeutic strategies and benchmarks to address ATC's inherent resistance mechanisms [28].

3 Targeted Therapies for Anaplastic Thyroid Carcinoma

Category	Feature	Method
Resistance Mechanisms and Challenges	Targeted Inhibition	TMT[30]
	Predictive Strategies	DL-KIP[31], VSI[21]
	Pathway Avoidance	PLX8394[18]

Table 1: This table provides a comprehensive overview of the resistance mechanisms and challenges associated with BRAF inhibitor therapies in anaplastic thyroid carcinoma. It categorizes the features and methods employed to address these challenges, including targeted inhibition, predictive strategies, and pathway avoidance, highlighting the specific methodologies such as TMT, DL-KIP, VSI, and PLX8394.

Table 2 presents a detailed summary of the mechanisms, clinical applications, and resistance challenges associated with BRAF inhibitor therapies in the context of anaplastic thyroid carcinoma treatment. In the realm of anaplastic thyroid carcinoma (ATC) treatment, BRAF inhibitors have become integral to targeted therapy strategies, particularly for tumors with the BRAFV600E mutation. This section examines the mechanisms and clinical applications of BRAF inhibitors, such as Dabrafenib and Trametinib, highlighting their role in the therapeutic landscape and their impact on patient outcomes within personalized medicine frameworks. As illustrated in Figure **??**, the targeted therapies for anaplastic thyroid carcinoma focus on BRAF inhibitors and their mechanisms, clinical applications, and the associated resistance mechanisms and challenges. Table 1 presents a detailed summary of the methods used to tackle resistance mechanisms and challenges in BRAF inhibitor therapies for anaplastic thyroid carcinoma. The hierarchical structure depicted in the figure emphasizes the disruption of the MAPK/ERK pathway by BRAF inhibitors, showcasing their effectiveness not only in ATC but also in other BRAF-mutated cancers, while also addressing the challenges posed by drug resistance and toxicity.

Figure 2: This figure illustrates the targeted therapies for anaplastic thyroid carcinoma, focusing on BRAF inhibitors and their mechanisms, clinical applications, and associated resistance mechanisms and challenges. The hierarchical structure highlights the disruption of the MAPK/ERK pathway by BRAF inhibitors, their effectiveness in ATC and other BRAF-mutated cancers, and the challenges posed by drug resistance and toxicity.

3.1 BRAF Inhibitors: Mechanisms and Clinical Applications

BRAF inhibitors, including Dabrafenib and Trametinib, are central to managing ATC characterized by the BRAFV600E mutation [20]. These agents disrupt the MAPK/ERK pathway, which is constitutively active in BRAFV600E-mutated tumors, thereby inhibiting tumor cell proliferation

and survival [20]. Dabrafenib targets the ATP-binding site of BRAF kinase, while Trametinib, a MEK inhibitor, prevents ERK activation, enhancing the blockade of this signaling cascade [20]. The combination of these inhibitors has shown a 38

Beyond ATC, BRAF inhibitors are also effective in other BRAF-mutated cancers, such as melanoma [20]. However, resistance mechanisms, including alternative pathway activation and secondary mutations, challenge their efficacy [20]. Next-generation inhibitors like PLX8394, which selectively target BRAF V600 mutations without activating the MAPK pathway, offer a promising solution to these challenges [20]. Additionally, BRAF inhibitors' potential in targeting oncogenic BRAF fusions underscores their versatility in personalized treatment approaches [23].

Figure 3 illustrates the key aspects of BRAF inhibitors, highlighting their mechanisms, clinical applications, and the challenges faced along with potential solutions. This figure emphasizes the efficacy of BRAF inhibitors, both alone and in combination with MEK inhibitors, in altering treatment responses such as complete and partial responses. Furthermore, it depicts the impact of compounds like ALA, LIM2405, and COLO 201 on cell proliferation, providing insights into their therapeutic potential [32, 18]. Collectively, these findings underscore the significance of BRAF inhibitors in managing cancers with BRAF mutations, offering personalized treatment options while addressing resistance mechanisms.



Figure 3: This figure illustrates the key aspects of BRAF inhibitors, highlighting their mechanisms, clinical applications, and the challenges faced along with potential solutions. These inhibitors play a significant role in managing cancers with BRAF mutations, offering personalized treatment options while addressing resistance mechanisms.

3.2 Resistance Mechanisms and Challenges

The efficacy of BRAF inhibitors in ATC is often compromised by drug resistance, which is a significant barrier to sustained treatment success [19]. Resistance involves intrinsic and acquired mechanisms that reactivate the MAPK/ERK pathway, including secondary mutations and alternative splicing [21]. A notable side effect of BRAF inhibitors is the paradoxical activation of the MAPK pathway, leading to cutaneous squamous cell carcinoma (cuSCC) [33]. Trametinib's targeting of KSR-MEK complexes offers a strategy to mitigate this effect and improve outcomes [30].

Combination therapies with BRAF and MEK inhibitors have reduced cuSCC incidence and enhanced efficacy [33]. Next-generation inhibitors like PLX8394, which avoid MAPK pathway activation, present a promising avenue for overcoming resistance in RAS-mutated cancers [18]. However, challenges such as low drug-loading efficiency and high toxicity remain [25]. Innovative predictive models integrating diverse data types show potential for improving treatment response predictions and personalizing therapeutic strategies [31].

Addressing resistance in receptor tyrosine kinase inhibitor (RTKI) therapies is crucial for enhancing treatment efficacy and improving outcomes in BRAFV600E-mutated ATC [20].

4 BRAF Inhibitors: Dabrafenib and Trametinib

The advancement of targeted therapies for anaplastic thyroid carcinoma (ATC) hinges on understanding the mechanisms of BRAF inhibitors. This section explores how Dabrafenib and Trametinib disrupt

Feature	BRAF Inhibitors: Mechanisms and Clinical Applications	Resistance Mechanisms and Challenges
Mechanism of Action	Mapk/erk Disruption	Mapk Reactivation
Clinical Applications	Atc, Melanoma	Combination Therapies
Resistance Challenges	Secondary Mutations	Cuscc, Toxicity

Table 2: This table provides a comprehensive comparison of the mechanisms, clinical applications, and resistance challenges associated with BRAF inhibitors used in the treatment of anaplastic thyroid carcinoma and other BRAF-mutated cancers. It highlights the disruption of the MAPK/ERK pathway as a primary mechanism of action, the use of combination therapies to enhance clinical outcomes, and the emergence of resistance mechanisms such as MAPK reactivation and secondary mutations.

the MAPK/ERK signaling cascade, crucial in BRAFV600E-mutated cancers, and their potential to overcome resistance.

4.1 Mechanisms of Action and Therapeutic Targets

Dabrafenib and Trametinib are critical in targeting BRAFV600E mutations in ATC by disrupting the MAPK/ERK pathway, a driver of tumorigenesis [34]. Dabrafenib inhibits BRAF kinase by binding to its ATP-binding site, reducing downstream MAPK/ERK signaling, thereby limiting cancer cell proliferation [1, 35]. Trametinib, a MEK inhibitor, blocks MEK1/2 kinases, preventing ERK activation and further suppressing the pathway [36]. Together, they provide a more comprehensive pathway inhibition compared to monotherapy [1].

Beyond BRAFV600E, Trametinib is explored for BRAF non-V600 mutations, broadening its application [36]. Combining these inhibitors addresses primary oncogenic drivers and mitigates monotherapy resistance [18]. Innovations like PLX8394 prevent RAF dimer formation, avoiding paradoxical MAPK activation, a common resistance mechanism [18], highlighting advancements in developing effective inhibitors with favorable safety profiles [5].

Predictive models, such as the KIEN method, enhance precision by forecasting drug effectiveness and identifying significant kinase targets, aligning with personalized medicine goals [37, 38].



(a) RAS/RAF/MAPK Pathway in Cancer and Beyond: A Timeline of Discoveries and Therapeutic Advances[39]



(b) A549 Selectivities[37]

Figure 4: Examples of Mechanisms of Action and Therapeutic Targets

As illustrated in Figure 5, the hierarchical structure of mechanisms and therapeutic targets involving BRAF inhibitors is depicted, highlighting targeted mutations and predictive models in cancer treatment. This figure emphasizes key innovations and applications in addressing both BRAFV600E and non-V600 mutations, as well as the role of predictive modeling in personalized medicine. The timeline in Figure 1(a) highlights the evolution of therapeutic advances, while Figure 1(b) shows kinase inhibitors' selectivity across cell lines, emphasizing specificity and potential off-target effects [39, 37].



Figure 5: This figure illustrates the hierarchical structure of mechanisms and therapeutic targets involving BRAF inhibitors, targeted mutations, and predictive models in cancer treatment. It highlights key innovations and applications in addressing BRAFV600E and non-V600 mutations, as well as the role of predictive modeling in personalized medicine.

Benchmark	Size	Domain	Task Format	Metric
ROAR[1]	206	Oncology	Overall Response Rate Assessment	Overall Response Rate, Progression-Free Survival
ATC-BM[15]	812	Oncology	Survival Analysis	Overall Survival, Incidence Rate
BRAFi-PTEN[32]	66	Oncology	Genomic Profiling	Progression-Free Survival, Overall Survival
BRAF-R[40]	132	Melanoma	Resistance Mechanism Identification	Overall Survival, Progression-Free Survival
ATC-TT[38]	16	Oncology	Efficacy Evaluation	PFS, OS
HGTC[41]	364	Thyroid Carcinoma	Survival Analysis	Disease Specific Survival, Distant Metastasis Free Survival
COMBI-MB[35]	125	Oncology	Clinical Trial Evaluation	Intracranial Response Rate, Overall Survival
RAS-BRAF[42]	4	Thyroid Cancer	Mutation Analysis	Mutation Frequency, Progression-Free Survival

Table 3: This table presents a comprehensive overview of various benchmarks utilized in the assessment of BRAF inhibitors across different domains, including oncology and melanoma. Key metrics such as overall survival, progression-free survival, and response rates are highlighted to evaluate the efficacy of these treatments in clinical and genomic contexts.

4.2 Clinical Trials and Efficacy

BRAF inhibitors, particularly Dabrafenib and Trametinib, have shown significant efficacy in clinical trials across various tumors, including ATC [5]. Table 3 provides a detailed overview of the benchmarks used in clinical trials to assess the efficacy of BRAF inhibitors, underscoring the diversity of task formats and metrics employed in evaluating treatment outcomes. These agents exhibit notable antitumor activity in BRAFV600E-positive tumors, leading to tumor regression and improved progression-free survival [18, 20]. Dabrafenib, alone or with Trametinib, achieves a 38

Their efficacy extends beyond ATC, with significant activity in various BRAF-mutated tumors [5]. Encorafenib, another BRAF inhibitor, shows distinct tolerability and activity in both BRAFi-pretreated and BRAFi-naive patients, highlighting the need for personalized regimens [5]. Next-generation inhibitors like PLX8394 effectively reduce paradoxical MAPK activation, offering alternatives for resistance cases [18].

4.3 Safety and Toxicity

The use of BRAF inhibitors like Dabrafenib and Trametinib in ATC therapy presents a distinct safety profile requiring careful management. While effective against BRAFV600E-mutated tumors, these inhibitors can cause cutaneous toxicities, notably cutaneous squamous-cell carcinoma (cuSCC), due to paradoxical MAPK activation [33]. Combining Dabrafenib with Trametinib reduces these

toxicities, enhancing safety [33]. Trametinib's mechanism counteracts MEK-dependent resistance, lowering skin-related adverse events [33].

Challenges remain, including resistance development and potential cardiotoxic effects with Trametinib, necessitating careful monitoring [4]. Continued research into toxicity mechanisms is essential for developing mitigation strategies, improving adherence, and optimizing outcomes [33]. Combining BRAF inhibitors with other agents or immune checkpoint inhibitors holds promise for overcoming resistance and enhancing therapeutic efficacy [33].

5 Immune Checkpoint Blockade in Anaplastic Thyroid Carcinoma

5.1 Mechanisms and Therapeutic Potential

Immune checkpoint blockade (ICB) has revolutionized cancer immunotherapy, offering new treatment avenues for anaplastic thyroid carcinoma (ATC) [13]. Key immune checkpoints, such as CTLA-4 and PD-1, regulate immune responses to maintain self-tolerance and prevent autoimmunity [6]. ATC cells can exploit these checkpoints to evade immune detection, promoting tumor persistence [7]. Immune checkpoint inhibitors (ICIs), like pembrolizumab, disrupt these pathways by inhibiting PD-1 on T cells and PD-L1 on tumor cells, reactivating T cells to target cancer cells [9]. The expression of PD-L1 in ATC tumors underscores the potential for ICIs to elicit robust antitumor responses in certain patients [8].

The efficacy of ICIs in ATC is challenged by resistance mechanisms, where tumors may activate alternative checkpoints or recruit immunosuppressive cells like MDSCs to avoid immune surveillance [22]. This necessitates innovative strategies to enhance ICB efficacy in ATC. Combining ICIs with other treatments, such as BRAF inhibitors, offers a promising strategy to overcome resistance and boost antitumor immunity [7]. BRAF inhibitors can modulate immune responses by upregulating chemokines that attract immune cells to the tumor microenvironment, enhancing the antitumor effects of ICIs [10].

The use of ICIs in ATC is associated with immune-related adverse events (irAEs), including hypothyroidism and thyroiditis, requiring careful management to optimize outcomes [12]. Integrating ICB with other therapies, such as BRAF inhibitors, holds promise for overcoming resistance and improving therapeutic efficacy in ATC. Continued research into tumor-immune interactions and refining ICB strategies are essential for discovering new therapeutic avenues and improving patient prognosis and survival. This is crucial given the challenges posed by tumor heterogeneity and the need for personalized treatment approaches, as highlighted by recent studies on immunological checkpoints and molecular pathways like PI3K/Akt in cancer progression and treatment resistance. Identifying predictive biomarkers and exploring combination therapies are vital to enhance the efficacy of ICB and other targeted therapies for advanced thyroid cancer [24, 13, 43, 6]. As our understanding of tumor-immune dynamics advances, strategically integrating ICB with targeted therapies offers a promising approach for managing this aggressive cancer.



(a) Predicting and Elucidating Mechanisms for Responders and Non-Responders to Immunotherapy in Cancer[13]



(b) Drug Pair's Selectivity for A549[37]

Figure 6: Examples of Mechanisms and Therapeutic Potential

Understanding the mechanisms influencing ICB efficacy in ATC is crucial. As shown in Figure 6, the first figure presents a flowchart for predicting and elucidating mechanisms for immunotherapy responders and non-responders, starting with mass cytometry and monocyte phenotype analysis and progressing through microbiome and tumor assessments to identify responders and non-response mechanisms. Such systematic approaches are vital for tailoring immunotherapy strategies to individual patients, enhancing treatment success. The second figure provides a bar chart of drug pair selectivity for the A549 cell line, a model for studying drug interactions. These insights into specific drug combinations targeting cancer cells can optimize therapeutic regimens for ATC. Together, these figures emphasize the importance of understanding patient-specific responses and drug selectivity in developing more effective and personalized cancer therapies [13, 37].

5.2 Immune-Related Adverse Events (irAEs)

ICB therapies represent a significant advance in managing anaplastic thyroid carcinoma (ATC), a notably aggressive cancer responsible for significant thyroid cancer mortality. By leveraging the immune system to target tumor cells, ICB therapies, including pembrolizumab, show potential when combined with conventional treatments like kinase inhibitors, potentially improving patient outcomes in this challenging disease. This is crucial given ATC's rapid progression and historically poor prognosis, with median survival rates remaining low despite aggressive treatment [8, 38, 44, 45, 46]. However, immune checkpoint inhibitors, particularly those targeting CTLA-4 and PD-1 pathways, are often associated with immune-related adverse events (irAEs), posing significant clinical management challenges.

These irAEs arise from the off-target effects of ICIs, which enhance the immune response against tumor cells but can also provoke excessive immune activation, leading to inflammatory side effects [9]. The range of irAEs is broad, affecting various organ systems, with hypothyroidism and thyroiditis being particularly relevant in ATC treatment [12].

Managing irAEs is challenging due to the lack of reliable predictive biomarkers to identify at-risk patients and the variability in irAE presentations, which can be diverse and atypical [47]. Consequently, a multidisciplinary approach involving oncologists, endocrinologists, dermatologists, and other specialists is essential for effectively managing these complex side effects.

Current research focuses on optimizing treatment strategies to mitigate irAEs while maintaining ICB therapeutic efficacy. This includes developing novel biomarkers to predict patient susceptibility to irAEs and refining therapeutic protocols to balance efficacy with safety. Additionally, integrating ICB with other therapies, such as BRAF inhibitors, may enhance antitumor efficacy while potentially reducing irAE incidence and severity [9].

6 Combination Therapies and Future Directions

6.1 Innovative Approaches in Targeted Therapy Development

Advancements in targeted therapies for anaplastic thyroid carcinoma (ATC) are addressing drug resistance and the tumor's complex molecular profile. Next-generation BRAF inhibitors like PLX8394 selectively inhibit BRAFV600E mutations, reducing adverse effects by avoiding paradoxical MAPK pathway activation [18]. This evolution in kinase inhibitor design aims to enhance efficacy and minimize side effects [18].

Combining BRAF inhibitors such as Dabrafenib with MEK inhibitors like Trametinib has improved treatment outcomes in BRAF-mutant melanoma by targeting multiple tumor growth pathways, thereby overcoming resistance and enhancing patient survival [48, 29, 35, 19, 36]. These combinations effectively block the MAPK/ERK signaling pathway, reducing resistance likelihood.

Moreover, pocket-aware peptide design enhances targeted therapy specificity and efficacy in ATC [3]. This strategy precisely targets molecular aberrations within BRAF and related pathways, improving outcomes and mitigating resistance [4].

Advanced predictive models like the KIEN method refine targeted therapies by predicting drug effectiveness and identifying significant kinase targets [37]. These models, integrating diverse data types, offer promising avenues for personalized therapeutic strategies, particularly in BRAFV600E-mutated ATC [31].

Ongoing research into ATC's molecular pathways and resistance mechanisms underscores the challenges of drug resistance and the need for innovative targeted therapies to improve treatment outcomes [11, 20, 25]. By leveraging predictive models and exploring combination therapies, there is potential to enhance treatment precision and efficacy for BRAFV600E-mutated ATC, crucial for overcoming drug resistance.

6.2 Current Understanding and Future Directions

Targeted therapies, notably BRAF inhibitors like Dabrafenib and Trametinib, have transformed ATC treatment, particularly in BRAFV600E mutation cases [1]. These agents effectively inhibit the MAPK/ERK signaling pathway, crucial for BRAFV600E-mutated ATC proliferation and survival [20]. Dabrafenib targets BRAF kinase, while Trametinib inhibits downstream MEK1/2 kinases, collectively blocking the signaling pathway.

Despite these advances, ATC treatment remains challenging due to resistance mechanisms, including secondary mutations and alternative pathways reactivating MAPK/ERK, compromising BRAF inhibitors' efficacy. Paradoxical MAPK activation can also lead to adverse effects like cutaneous squamous cell carcinoma (cuSCC) [33].

Future research should refine combination therapies and explore personalized medicine trends [43]. Integrating BRAF inhibitors with other agents or immune checkpoint inhibitors shows promise in overcoming resistance and enhancing efficacy. Next-generation BRAF inhibitors like PLX8394, which selectively inhibit BRAF V600 mutations without paradoxical MAPK activation, offer a strategy to address resistance in RAS-mutated cancers [18].

Exploring molecular pathways in ATC, particularly MAPK/ERK signaling and BRAF mutations, remains critical. Dysregulation of these pathways contributes to ATC's aggressive phenotype and therapeutic resistance, necessitating continued innovation in targeted therapy [29]. Predictive models like the KIEN method enhance targeted therapy precision by predicting drug effectiveness and identifying kinase targets [37].

The tumor microenvironment's interaction with genetic alterations in ATC is an emerging interest area. Comprehensive understanding of molecular interactions in ATC is crucial for innovative strategies targeting its unique architecture. This knowledge facilitates precision medicine approaches using genomic analysis and optimized drug delivery systems to enhance efficacy and minimize toxicity, addressing drug resistance and pharmacological limitations [30, 31, 25, 49]. Future directions should explore MAPK/ERK pathway dysregulation and alternative pathways like PI3K/AKT/mTOR to improve outcomes.

Integrating predictive models like the KIEN method further enhances targeted therapy precision by predicting drug effectiveness and identifying kinase targets [37]. Such approaches align with personalized medicine, optimizing strategies based on tumor molecular characteristics [38].

Recent studies highlight MAPK/ERK pathway inhibitors like PLX8394 in overcoming ATC resistance mechanisms [18]. Next-generation inhibitors offer a promising strategy to address drug resistance and improve outcomes [18]. Continued research into ATC's molecular pathways and novel targeted therapies will be critical for advancing the field and enhancing patient outcomes.

7 Immune Checkpoint Blockade in Anaplastic Thyroid Carcinoma

The exploration of immune checkpoint blockade (ICB) in anaplastic thyroid carcinoma (ATC) represents a critical advancement in oncological therapeutics, particularly given the aggressive nature of this malignancy and its propensity for rapid progression. As we delve into the mechanisms and therapeutic potential of ICB, it is essential to understand how these therapies can be strategically employed to enhance the immune response against ATC. This understanding not only elucidates the biological underpinnings of immune evasion by tumor cells but also lays the groundwork for innovative treatment strategies aimed at improving patient outcomes. The subsequent subsection will provide an in-depth analysis of these mechanisms and the associated therapeutic implications.

7.1 Mechanisms and Therapeutic Potential

The advent of immune checkpoint blockade (ICB) therapies has revolutionized the treatment landscape for various cancers, including anaplastic thyroid carcinoma (ATC), by harnessing the body's immune system to target and eliminate tumor cells [6]. Immune checkpoints such as CTLA-4 and PD-1 are pivotal in maintaining self-tolerance and preventing autoimmune reactions by modulating the immune response [6]. However, cancer cells, including those of ATC, can exploit these pathways to evade immune detection and destruction, promoting tumor survival and progression [7].

The therapeutic potential of immune checkpoint inhibitors (ICIs), such as pembrolizumab, lies in their ability to block these inhibitory pathways, thereby reactivating T cells and restoring their ability to recognize and eliminate cancer cells [10]. The expression of PD-L1 in ATC tumors presents a promising target for ICIs, particularly in patients with BRAFV600E mutations [8]. The combination of BRAF inhibitors with immune checkpoint inhibitors has demonstrated a synergistic effect, further enhancing antitumor responses and providing a potential strategy to overcome resistance mechanisms that often arise in ATC treatment [10].

Despite these promising developments, the application of ICIs in ATC is not without challenges. Resistance mechanisms, both intrinsic and acquired, continue to pose significant hurdles, necessitating a deeper understanding of the tumor-immune dynamics and the development of strategies to overcome these barriers [11]. Furthermore, the endocrine toxicities associated with ICIs, such as hypothyroidism and thyroiditis, require careful management to mitigate adverse effects and improve patient outcomes [12].

Ongoing research into the tumor-immune interactions and the refinement of ICB approaches hold the potential to unlock new avenues for effective ATC treatment, ultimately improving patient prognosis and survival . The incorporation of immune checkpoint blockade (ICB) into the treatment strategies for anaplastic thyroid cancer (ATC) marks a pivotal advancement in leveraging the body's immune system to effectively target and manage this particularly aggressive form of cancer, as recent research highlights the potential of ICB to enhance patient outcomes despite the challenges posed by tumor heterogeneity and immune resistance. [2, 13, 6]

7.2 Current Understanding and Future Directions

The treatment paradigm for anaplastic thyroid carcinoma (ATC) is rapidly evolving, with combination therapies featuring prominently in emerging strategies aimed at overcoming the intrinsic challenges of drug resistance and tumor heterogeneity . The rationale behind combining BRAF inhibitors like Dabrafenib and Trametinib with immune checkpoint inhibitors stems from their complementary mechanisms of action, which can potentiate antitumor effects and mitigate resistance mechanisms [18].

The potential of combination therapies is underscored by the observed synergistic effects when BRAF inhibitors are used in conjunction with immune checkpoint inhibitors. This approach leverages the ability of BRAF inhibitors to modulate the tumor microenvironment, enhancing the infiltration and activation of immune cells, which can amplify the antitumor effects of immune checkpoint blockade [10]. Furthermore, the combination of these therapeutic modalities has demonstrated the potential to overcome resistance mechanisms that often limit the efficacy of monotherapy [42].

The current landscape of combination therapies for ATC is characterized by a focus on integrating BRAF inhibitors with immune checkpoint inhibitors, such as pembrolizumab, to enhance antitumor responses and improve clinical outcomes [10]. This approach is supported by preclinical and clinical evidence, which suggests that the synergistic effects of combining BRAF inhibitors with immune checkpoint inhibitors can lead to more durable responses and prolonged survival in patients with BRAFV600E-mutated ATC [10].

Despite the promising potential of combination therapies, challenges remain in optimizing treatment regimens to balance efficacy with safety and minimize the risk of adverse events . The development of innovative approaches, such as the use of predictive models to tailor treatment regimens based on individual tumor characteristics, holds promise for improving the precision and effectiveness of combination therapies [37].

Future research directions in ATC treatment are likely to focus on the integration of novel targeted therapies with immune checkpoint inhibitors, aiming to enhance antitumor efficacy and overcome re-

sistance mechanisms. This includes the exploration of new therapeutic targets within the MAPK/ERK pathway and the development of next-generation inhibitors with improved selectivity and reduced toxicity . Additionally, understanding the complex interplay between tumor cells and the immune system, including the role of myeloid-derived suppressor cells (MDSCs) in modulating immune responses, will be crucial for optimizing combination therapy strategies [22].

The integration of advanced predictive models, such as the KIEN method, which utilizes regression models built from in vitro cell responses, offers a promising avenue for personalizing treatment regimens and improving therapeutic outcomes [37]. These models have demonstrated potential in predicting the effectiveness of untested drugs and identifying statistically significant kinase targets, thereby enhancing the precision of targeted therapies for anaplastic thyroid carcinoma [37].

7.3 Current Understanding and Future Directions

8 Conclusion

Anaplastic thyroid carcinoma (ATC) remains a formidable challenge in oncology due to its aggressive nature and limited survival rates. Advances in targeted therapies, particularly through the use of BRAF inhibitors such as Dabrafenib and Trametinib, have significantly reshaped treatment strategies by targeting the MAPK/ERK pathway, which is often activated by BRAFV600E mutations. These inhibitors have demonstrated efficacy in impeding tumor progression, yet their clinical utility is frequently hindered by resistance development and associated toxicities. Genetic profiling, including the identification of mutations like BRAF, is crucial for optimizing treatment plans and enhancing patient management.

The integration of immune checkpoint inhibitors (ICIs), such as pembrolizumab, marks a pivotal development in ATC therapy. By blocking inhibitory immune pathways, these agents reinvigorate T cell activity, offering potential for robust antitumor responses. However, the management of resistance mechanisms and immune-related adverse events remains essential in maximizing therapeutic benefits. The exploration of combination therapies, particularly those that pair BRAF inhibitors with ICIs, shows promise in enhancing efficacy and overcoming resistance, aligning with the personalized medicine approach that tailors treatment to the genetic and molecular characteristics of tumors.

Emerging therapies, including next-generation BRAF inhibitors like PLX8394, which target mutant BRAF signaling without inducing paradoxical MAPK activation, provide a promising avenue for overcoming therapeutic resistance. Continued research is imperative to refine these approaches and address resistance mechanisms. The potential of new technologies, such as artificial intelligence, to enhance receptor tyrosine kinase inhibitor development and improve diagnostic precision, represents a significant advancement in the field. Additionally, targeting alternative pathways, such as the PI3K/Akt pathway, alongside existing therapies, holds promise for further improving patient outcomes. Advanced predictive models, like the KIEN method, offer potential for enhancing the precision of targeted therapies by predicting drug effectiveness and identifying key kinase targets, further underscoring the importance of ongoing innovation in the treatment of ATC.

References

[1] Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y Wen, Sascha Dietrich, Maja JA de Jonge, Jean-Yves Blay, et al. Dabrafenib plus trametinib in brafv600e-mutated rare cancers: the phase 2 roar trial. *Nature medicine*, 29(5):1103–1112, 2023.

[2] Preety Priya and Vicente M. Reyes. A cancer biotherapy resource, 2015.

[3] Po-Yu Liang and Jun Bai. E(3)-invaraint diffusion model for pocket-aware peptide generation, 2024.

[4] Liling Huang, Shiyu Jiang, and Yuankai Shi. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). *Journal of hematology & oncology*, 13:1–23, 2020.

[5] Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F Kefford, et al. Phase i dose-escalation and-expansion study of the braf inhibitor encorafenib (lgx818) in metastatic braf-mutant melanoma. *Clinical Cancer Research*, 23(18):5339–5348, 2017.

[6] Arlene H Sharpe. Introduction to checkpoint inhibitors and cancer immunotherapy. *Immunological reviews*, 276(1):5, 2017.

[7] Eika S Webb, Peng Liu, Renato Baleeiro, Nicholas R Lemoine, Ming Yuan, and Yaohe Wang. Immune checkpoint inhibitors in cancer therapy. *Journal of biomedical research*, 32(5):317, 2017.

[8] Priyanka C Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D Williams, G Brandon Gunn, Horiana Grosu, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. *Journal for immunotherapy of cancer*, 6:1–10, 2018.

[9] Xiao Han, Hongjun Li, Daojia Zhou, Zhaowei Chen, and Zhen Gu. Local and targeted delivery of immune checkpoint blockade therapeutics. *Accounts of chemical research*, 53(11):2521–2533, 2020.

[10] Laura Croce, Francesca Coperchini, Flavia Magri, Luca Chiovato, and Mario Rotondi. The multifaceted anti-cancer effects of braf-inhibitors. *Oncotarget*, 10(61):6623, 2019.

[11] Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. *Signal transduction and targeted therapy*, 6(1):201, 2021.

[12] Jordan J Wright, Alvin C Powers, and Douglas B Johnson. Endocrine toxicities of immune checkpoint inhibitors. *Nature Reviews Endocrinology*, 17(7):389–399, 2021.

[13] Young-Jun Park, Da-Sol Kuen, and Yeonseok Chung. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. *Experimental & molecular medicine*, 50(8):1–13, 2018.

[14] Adalberto Miranda-Filho, Joannie Lortet-Tieulent, Freddie Bray, Bochen Cao, Silvia Franceschi, Salvatore Vaccarella, and Luigino Dal Maso. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *The lancet Diabetes & endocrinology*, 9(4):225–234, 2021.

[15] Mischa de Ridder, Els Nieveen van Dijkum, Anton Engelsman, Ellen Kapiteijn, Heinz-Josef Klümpen, and Coen RN Rasch. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the netherlands over 3 decades. *European journal of endocrinology*, 183(2):203–209, 2020.

[16] Valentina Di Salvatore, Fiorenza Gianì, Giulia Russo, Marzio Pennisi, Pasqualino Malandrino, Francesco Frasca, and Francesco Pappalardo. Gene expression and pathway bioinformatics analysis detect a potential predictive value of map3k8 in thyroid cancer progression, 2019.

[17] Evan Olson, Grant Wintheiser, Katrina M Wolfe, Jonathan Droessler, and Peter T Silberstein. Epidemiology of thyroid cancer: a review of the national cancer database, 2000-2013. *Cureus*, 11(2), 2019.

[18] Candani SA Tutuka, Miles C Andrews, John M Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, and Andreas Behren. Plx8394, a new generation braf inhibitor, selectively inhibits braf in colonic adenocarcinoma cells and prevents paradoxical mapk pathway activation. *Molecular cancer*, 16:1–5, 2017.

[19] Merope Griffin, Daniele Scotto, Debra H Josephs, Silvia Mele, Silvia Crescioli, Heather J Bax, Giulia Pellizzari, Matthew D Wynne, Mano Nakamura, Ricarda M Hoffmann, et al. Braf inhibitors: resistance and the promise of combination treatments for melanoma. *Oncotarget*, 8(44):78174, 2017.

[20] Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée, and Nor Eddine Sounni. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. *Cancers*, 12(3):731, 2020.

[21] Patrick C. Kinnunen, Siddhartha Srivastava, Zhenlin Wang, Kenneth K. Y. Ho, Brock A. Humphries, Siyi Chen, Jennifer J. Linderman, Gary D. Luker, Kathryn E. Luker, and Krishna Garikipati. Inference of weak-form partial differential equations describing migration and proliferation mechanisms in wound healing experiments on cancer cells, 2024.

[22] Shannon M Steinberg, Tamer B Shabaneh, Peisheng Zhang, Viktor Martyanov, Zhenghui Li, Brian T Malik, Tamara A Wood, Andrea Boni, Aleksey Molodtsov, Christina V Angeles, et al. Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to braf inhibitors. *Cancer research*, 77(7):1599–1610, 2017.

[23] Alison M Schram, Matthew T Chang, Philip Jonsson, and Alexander Drilon. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. *Nature reviews Clinical oncology*, 14(12):735–748, 2017.

[24] Diprajan Laha, Naris Nilubol, and Myriem Boufraqech. New therapies for advanced thyroid cancer. *Frontiers in endocrinology*, 11:82, 2020.

[25] Mandana T Manzari, Yosi Shamay, Hiroto Kiguchi, Neal Rosen, Maurizio Scaltriti, and Daniel A Heller. Targeted drug delivery strategies for precision medicines. *Nature Reviews Materials*, 6(4):351–370, 2021.

[26] Yassine Habchi, Yassine Himeur, Hamza Kheddar, Abdelkrim Boukabou, Shadi Atalla, Ammar Chouchane, Abdelmalik Ouamane, and Wathiq Mansoor. Ai in thyroid cancer diagnosis: Techniques, trends, and future directions, 2023.

[27] Enas Younis. Oncogenesis of thyroid cancer. *Asian Pacific journal of cancer prevention: APJCP*, 18(5):1191, 2017.

[28] Rossella Salemi, Luca Falzone, Gabriele Madonna, Jerry Polesel, Diana Cinà, Domenico Mallardo, Paolo A Ascierto, Massimo Libra, and Saverio Candido. Mmp-9 as a candidate marker of response to braf inhibitors in melanoma patients with braf v600e mutation detected in circulating-free dna. *Frontiers in pharmacology*, 9:856, 2018.

[29] April KS Salama, Shuli Li, Erin R Macrae, Jong-In Park, Edith P Mitchell, James A Zwiebel, Helen X Chen, Robert J Gray, Lisa M McShane, Larry V Rubinstein, et al. Dabrafenib and trametinib in patients with tumors with brafv600e mutations: results of the nci-match trial subprotocol h. *Journal of Clinical Oncology*, 38(33):3895–3904, 2020.

[30] Zaigham M Khan, Alexander M Real, William M Marsiglia, Arthur Chow, Mary E Duffy, Jayasudhan R Yerabolu, Alex P Scopton, and Arvin C Dar. Structural basis for the action of the drug trametinib at ksr-bound mek. *Nature*, 588(7838):509–514, 2020.

[31] Niranjan Balachandar, Christine Liu, and Winston Wang. Prediction of small molecule kinase inhibitors for chemotherapy using deep learning, 2019.

[32] Federica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, Douglas B Johnson, Katherine S Panageas, Parisa Momtaz, Catherine Higham, Helen H Won, James J Harding, Taha Merghoub, et al. Pten loss-of-function alterations are associated with intrinsic resistance to braf inhibitors in metastatic melanoma. *JCO Precision Oncology*, 1:1–15, 2017.

[33] Ling Peng, Yina Wang, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, and Qiong Zhao. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent braf inhibitor and dual braf/mek inhibitors in cancer patients: a meta-analysis. *Oncotarget*, 8(47):83280, 2017.

[34] Federica Padovano and Chiara Villa. The development of drug resistance in metastatic tumours under chemotherapy: an evolutionary perspective, 2024.

[35] Michael A Davies, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Keith T Flaherty, Ana Arance, Vanna Chiarion-Sileni, Luc Thomas, Thierry Lesimple, Laurent Mortier, et al. Dabrafenib plus trametinib in patients with brafv600-mutant melanoma brain metastases (combi-mb): a multicentre, multicohort, open-label, phase 2 trial. *The Lancet Oncology*, 18(7):863–873, 2017.

[36] Douglas B Johnson, Fengmin Zhao, Marcus Noel, Gregory J Riely, Edith P Mitchell, John J Wright, Helen X Chen, Robert J Gray, Shuli Li, Lisa M McShane, et al. Trametinib activity in patients with solid tumors and lymphomas harboring braf non-v600 mutations or fusions: results from nci-match (eay131). *Clinical Cancer Research*, 26(8):1812–1819, 2020.

[37] Trish Tran, Edison Ong, Andrew P. Hodges, Giovanni Paternostro, and Carlo Piermarocchi. Prediction of kinase inhibitor response using activity profiling, in-vitro screening, and elastic net regression, 2013.

[38] Priyanka C Iyer, Ramona Dadu, Renata Ferrarotto, Naifa L Busaidy, Mouhammed A Habra, Mark Zafereo, Neil Gross, Kenneth R Hess, Maria Gule-Monroe, Michelle D Williams, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. *Thyroid*, 28(1):79–87, 2018.

[39] Md Entaz Bahar, Hyun Joon Kim, and Deok Ryong Kim. Targeting the ras/raf/mapk pathway for cancer therapy: from mechanism to clinical studies. *Signal transduction and targeted therapy*, 8(1):455, 2023.

[40] Stephen A Luebker and Scott A Koepsell. Diverse mechanisms of braf inhibitor resistance in melanoma identified in clinical and preclinical studies. *Frontiers in oncology*, 9:268, 2019.

[41] <div style="text-align: center;".

[42] Maria E Cabanillas, Ramona Dadu, Pryianka Iyer, Kacey B Wanland, Naifa L Busaidy, Anita Ying, Maria Gule-Monroe, Jennifer R Wang, Mark Zafereo, and Marie-Claude Hofmann. Acquired secondary ras mutation in brafv600e-mutated thyroid cancer patients treated with braf inhibitors. *Thyroid*, 30(9):1288–1296, 2020.

[43] Yan He, Miao Miao Sun, Guo Geng Zhang, Jing Yang, Kui Sheng Chen, Wen Wen Xu, and Bin Li. Targeting pi3k/akt signal transduction for cancer therapy. *Signal transduction and targeted therapy*, 6(1):425, 2021.

[44] Behrouz Salehian, Simon Y Liem, Hoda Mojazi Amiri, and Ellie Maghami. Clinical trials in management of anaplastic thyroid carcinoma; progressions and set backs: a systematic review. *International Journal of Endocrinology and Metabolism*, 17(1):e67759, 2019.

[45] Mariana Amaral, Ricardo A Afonso, M Manuela Gaspar, and Catarina Pinto Reis. Anaplastic thyroid cancer: How far can we go? *Excli Journal*, 19:800, 2020.

[46] Efstathios T Pavlidis, Ioannis N Galanis, and Theodoros E Pavlidis. Update on current diagnosis and management of anaplastic thyroid carcinoma. *World Journal of Clinical Oncology*, 14(12):570, 2023.

[47] Lucie Heinzerling, Enrico N De Toni, Georg Schett, Gheorghe Hundorfean, and Lisa Zimmer. Checkpoint inhibitors: the diagnosis and treatment of side effects. *Deutsches Ärzteblatt International*, 116(8):119, 2019.

[48] Jaquelyn N Sanchez, Ton Wang, and Mark S Cohen. Braf and mek inhibitors: use and resistance in braf-mutated cancers. *Drugs*, 78(5):549–566, 2018.

[49] Kaifu Gao, Duc D Nguyen, Meihua Tu, and Guo-Wei Wei. Generative network complex for the automated generation of druglike molecules, 2020.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.